Objective To investigate the efficacy and safety of microwave ablation(MWA)versus hepatic resection(HR)in the treatment of hepatocellular carcinoma(HCC)with liver cirrhosis using a meta-analysis.Methods This study was conducted according to the PRISMA guideline,with a PROSPERO registration number of CRD42024509185.PubMed,the Cochrane Library,EMBASE,Web of Science,CNKI,VIP,and Wanfang Data were searched for randomized controlled trials(RCTs)and cohort studies on MWA versus HR in the treatment of HCC with liver cirrhosis published up to November 2023,and Stata 12.0 was used to perform the meta-analysis.Results A total of 3 RCTs and 5 retrospective cohort studies were included,with 953 patients in total.The meta-analysis showed that there were no differences between MWA and HR in 1-,2-,3-,and 5-year overall survival(OS)rates(all P>0.05)and 1-,2-,and 5-year recurrence rates(all P>0.05).Compared with HR,MWA had a significantly higher 3-year recurrence rate(risk ratio[RR]=1.59,95%confidence interval[CI]:1.08-2.33,P=0.017)and significantly lower 1-,3-,and 5-year disease-free survival(DFS)rates(1-year DFS rate:RR=0.94,95%CI:0.89-0.99,P=0.018,I2=0.0%;3-year DFS rate:RR=0.84,95%CI:0.72-0.98,P=0.023,I2=25.4%;5-year DFS rate:RR=0.75,95%CI:0.58-0.98,P=0.032,I2=34.6%).However,subgroup analysis showed that there were no significant differences between MWA and HR in 1-,2-,and 3-year OS rates and 1-and 3-year DFS rates in the RCT subgroup(all P>0.05).Compared with HR,MWA had significantly better intraoperative blood loss(standardized mean difference[SMD]=-2.31,95%CI:-2.64 to-1.97,P<0.001,I2=3.1%),time of operation(SMD=-3.38,95%CI:-4.05 to-2.71,P<0.001,I2=73.8%),length of hospital stay(SMD=-2.54,95%CI:-3.27 to-1.80,P<0.001,I2=92.8%),adverse reactions(RR=0.42,95%CI:0.30-0.59,P<0.001,I2=0.0%),and liver function(SMD=-1.43,95%CI:-1.89--0.97,P<0.001).Conclusion There are no significant differences between MWA and HR in local recurrence,DFS,and OS,but MWA tends to have a less intraoperative blood loss,a shorter time of operation,fewer adverse reactions,a less impact on liver function,and a shorter length of hospital stay.

OBJECTIVETo establish a highly sensitive fluorometric nanobiosensor for determination of aqueous mercury ions (Hg(2+)) using optimized mercury-specific oligonucleotide (MSO) probes and graphene oxide (GO).

METHODSThe nanobiosensor was assembled by attaching the self-designed MSO(1) (5' end labeled with fluorophore carboxyfluorescein (FAM), denoted as FAM-MSO(1)) and MSO(2) to the surface of GO through strong non-covalent bonding forces. Upon the addition of Hg(2+), the formation of the T-Hg(2+)-T configuration desorbed the FAM-MSO(1) and MSO(2) from the surface of GO, resulting in a restoration of the fluorescence of FAM-MSO(1). Using the specific mispairing of T-Hg(2+)-T and the changes in fluorescent signals in solutions, quantitative analysis of Hg(2+) could be performed.

RESULTSThe average thickness of the prepared GO sheets was only 1.4 nm. For the Hg(2+) nanobiosensor, the optimum concentrations of FAM-MSO(1) and MSO(2) were both 1 µmol/L, the optimum volume of 0.5 g/L GO was 5 µL, and the limit of detection was 10 pmol/L; it had low cross-reactivity with 10 other kinds of non-specific metal ions; the fluorescence recovery efficiency was up to 65% in the re-determination of Hg(2+) after addition of Na(2)S(2)O(3).

CONCLUSIONThe MSO/GO-based nanobiosensor is convenient to operate, highly sensitive, highly specific, highly accurate, and reusable. It can be applied to determine trace amount of Hg(2+) in aqueous solutions.

Biosensing Techniques ; Fluorometry ; Graphite ; Mercury ; analysis ; Nanotechnology ; Oligonucleotide Probes ; Water